Introduction: Bone scan is most commonly performed scan in nuclear medicine. There exists a relationship between bone scan and bisphosphonate therapy because after bisphosphonate therapy bone scan is mandatory. Optical scintigraphy and magnetic resonance imaging are two emerging molecular imaging methods used to test bone physiology. This review focuses on nuclear bone scintigraphy since it is the most well-established method with a large body of research data to back it up in clinical practice. The radionuclides technetium-99m (Tc-99m) and fluoride-18 are commonly used in bone nuclear scintigraphy (F-18). Tc-99m and F-18 are generally correlated with Medtronic destructive (Tc-99m MDP) and fluoride and sodium, respectively (F-18 NaF). The decay of photons from the radioisotope is captured by a nuclear camera holding a salt valuable stone after these particles are inserted intravenously. This is accomplished by the shimmering or fluorescence technique, which occurs when a photon emitted by a radionuclide collides with a salt useful stone within a nuclear camera. Methodology: It was an Observational study of 30 patients conducted at Department of Nuclear Medicine, INMOL Lahore from November 2020-February 2021. Cancer patients of both male and female genders receiving bisphosphonate therapies were included in this study. The age and gender matched patients were included. Objective: The aim of the research was to see how bisphosphonates affected oncology patients' bone scans. The key goal of this research was to see how bisphosphonates therapy affected bone scan. Results and Conclusion: The overall uptake of radiopharmaceutical in bone tends to increase after bisphosphonates therapy. The relationship between the bisphosphonate therapy given to the patients and their bone scan is significant. The study hypothesis is accepted that bisphosphonate. Hence effect of bisphosphonate therapy on skeletal system can be monitored by bone scan.